These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16282723)

  • 21. Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy.
    Di Francia R; Siesto RS; Valente D; Spart D; Berretta M
    Eur Rev Med Pharmacol Sci; 2012 Sep; 16(9):1211-7. PubMed ID: 23047504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacogenomics and chemotherapy].
    Paris I; Cappellini GC; Malaguti P; Bassanelli M; Marchetti P
    Recenti Prog Med; 2010; 101(7-8):277-82. PubMed ID: 20842953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
    Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
    Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversing resistance to targeted therapy.
    Vidal L; Attard G; Kaye S; De Bono J
    J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
    Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
    Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
    Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
    Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
    Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
    Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomics in colorectal cancer.
    Lenz HJ
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):47-53. PubMed ID: 14523795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Problems in the current target therapy of malignancies].
    Stukov AN; Gershanovich ML; Filov VA; Imianitov EN
    Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022
    [No Abstract]   [Full Text] [Related]  

  • 34. Combinations of targeted therapies take aim at multiple pathways.
    Goldman B
    J Natl Cancer Inst; 2003 Nov; 95(22):1656-7. PubMed ID: 14625255
    [No Abstract]   [Full Text] [Related]  

  • 35. [Molecular targeted therapy for malignant brain tumors].
    Okamura T; Kurisu K
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
    [No Abstract]   [Full Text] [Related]  

  • 36. Gene expression signatures associated with the resistance to imatinib.
    Chung YJ; Kim TM; Kim DW; Namkoong H; Kim HK; Ha SA; Kim S; Shin SM; Kim JH; Lee YJ; Kang HM; Kim JW
    Leukemia; 2006 Sep; 20(9):1542-50. PubMed ID: 16855633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic lethality: killing cancer with cancer.
    Garber K
    J Natl Cancer Inst; 2002 Nov; 94(22):1666-8. PubMed ID: 12441317
    [No Abstract]   [Full Text] [Related]  

  • 38. Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents.
    Rochat B
    Curr Cancer Drug Targets; 2009 Aug; 9(5):652-74. PubMed ID: 19686091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib.
    Théou N; Gil S; Devocelle A; Julié C; Lavergne-Slove A; Beauchet A; Callard P; Farinotti R; Le Cesne A; Lemoine A; Faivre-Bonhomme L; Emile JF
    Clin Cancer Res; 2005 Nov; 11(21):7593-8. PubMed ID: 16278376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
    Speight RA; Nicolle A; Needham SJ; Verrill MW; Bryon J; Panter S
    J Clin Oncol; 2013 Jun; 31(16):e245-7. PubMed ID: 23610110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.